COSCIENS Biopharma (CSCI) 6-K 3 Nov 22 Current report (foreign) Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2022
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38064
Entity Registrant Name	Aeterna Zentaris Inc.
Entity Central Index Key	0001113423
Entity Address, Address Line One	c/o Norton Rose Fulbright Canada, LLP
Entity Address, Address Line Two	222 Bay Street
Entity Address, Address Line Three	Suite 3000, PO Box 53
Entity Address, City or Town	Toronto ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	M5K 1E7

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Financial Position (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 53,816	$ 65,300
Trade and other receivables (note 4)	777	1,314
Inventory	238	73
Income taxes receivable	1,305	2,361
Prepaid expenses and other current assets (note 5)	2,474	1,772
Total current assets	58,610	70,820
Restricted cash equivalents	300	335
Right of use assets	85	150
Property, plant and equipment	40	42
Identifiable intangible assets	537	625
Goodwill	7,034	8,130
Total Assets	66,606	80,102
Current liabilities
Payables and accrued liabilities (note 6)	2,287	2,672
Current portion of provisions	25	34
Income taxes payable	99	115
Current portion of deferred revenues (note 3)	3,484	4,815
Current portion of lease liabilities	73	130
Total current liabilities	5,968	7,766
Deferred revenues (note 3)	1,462	1,493
Deferred gain	85	98
Lease liabilities	16	31
Employee future benefits (note 7)	9,458	17,485
Provisions	199	243
Total liabilities	17,188	27,116
SHAREHOLDERS’ EQUITY
Share capital (note 8)	293,410	293,410
Warrants (note 8)	5,085	5,085
Other capital (note 8)	90,291	89,788
Deficit	(338,664)	(334,619)
Accumulated other comprehensive loss (“AOCI”)	(704)	(678)
Total shareholders’ equity	49,418	52,986
Total liabilities and shareholders’ equity	$ 66,606	$ 80,102

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Issued capital [member]	Warrants [member]	Other equity interest [member]	Retained earnings [member]	Accumulated Other Comprehensive Loss Income [member]	Total
Beginning balance at Dec. 31, 2020	$ 235,008	$ 12,402	$ 89,505	$ (322,659)	$ (1,045)	$ 13,211
Beginning balance, shares at Dec. 31, 2020	2,507,145
IfrsStatementLineItems [Line Items]
Net loss				(5,474)		(5,474)
Foreign currency translation adjustments					460	460
Actuarial gain on defined benefit plans				133		133
Comprehensive loss				(5,341)	460	(4,881)
Share-based compensation costs			292			292
Issuance of common shares, net of transaction costs	$ 29,081	1,897				30,978
Issuance of common shares, net of transaction costs, shares	943,448
Exercise of warrants	$ 29,770	(9,728)				20,042
Exercise of warrants, shares	1,400,447
Transfer of warrant issuance costs upon 2021 exercise of warrants (note 8)	$ (532)	532
Exercise of deferred share units (note 8)	$ 20		(28)			(8)
Exercise of deferred share units (note 8), shares	840
Ending balance at Sep. 30, 2021	$ 293,347	5,103	89,769	(328,000)	(585)	59,634
Ending balance, shares at Sep. 30, 2021	4,851,880
Beginning balance at Dec. 31, 2021	$ 293,410	5,085	89,788	(334,619)	(678)	52,986
Beginning balance, shares at Dec. 31, 2021	4,855,876
IfrsStatementLineItems [Line Items]
Net loss				(10,276)		(10,276)
Foreign currency translation adjustments					(26)	(26)
Actuarial gain on defined benefit plans				6,231		6,231
Comprehensive loss				(4,045)	(26)	(4,071)
Share-based compensation costs			503			503
Ending balance at Sep. 30, 2022	$ 293,410	$ 5,085	$ 90,291	$ (338,664)	$ (704)	$ 49,418
Ending balance, shares at Sep. 30, 2022	4,855,876

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues (note 3)
License fees	$ 605	$ 293	$ 831	$ 1,309
Development Services	1,202	684	2,091	2,809
Product sales			57
Royalties	14	20	57	47
Supply chain	39	55	119	139
Total revenues	1,860	1,052	3,155	4,304
Operating expenses
Cost of sales	14	31	106	72
Research and development expenses	3,293	1,485	8,081	4,711
General and administrative expenses	2,057	1,228	5,396	4,137
Selling expenses	217	360	822	924
Total operating expenses	5,581	3,104	14,405	9,844
Loss from operations	(3,721)	(2,052)	(11,250)	(5,540)
Gain (loss) due to changes in foreign currency exchange rates	301	124	977	(42)
Other finance costs		(4)	(3)	(21)
Net finance income (costs)	301	120	974	(63)
Loss before income taxes	(3,420)	(1,932)	(10,276)	(5,603)
Income tax recovery				129
Net loss	(3,420)	(1,932)	(10,276)	(5,474)
Items that may be reclassified subsequently to profit or loss:
Foreign currency translation adjustments	(105)	39	(26)	460
Items that will not be reclassified to profit or loss:
Actuarial gain (loss) on defined benefit plans and remeasurement of the net defined benefit liability (note 7)	(1,794)	219	6,231	133
Comprehensive loss	$ (5,319)	$ (1,674)	$ (4,071)	$ (4,881)
Net loss per share [basic and diluted]	$ (0.70)	$ (0.40)	$ (2.12)	$ (1.21)
Weighted average number of shares outstanding (note 11):
Basic	4,855,876	4,851,880	4,855,876	4,509,731
Diluted	4,855,876	4,851,880	4,855,876	4,509,731

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss for the period	$ (3,420)	$ (1,932)	$ (10,276)	$ (5,474)
Items not affecting cash and cash equivalents:
Provision	7	19	12	39
Depreciation and amortization	33	33	104	105
Share-based compensation costs	443	19	503	292
Employee future benefits (note 7)	69	50	266	149
Amortization of deferred revenues	(1,248)	(527)	(1,952)	(1,601)
Foreign exchange on items denominated in foreign currencies		(45)		82
Gain on disposal of property, plant and equipment				(1)
Interest accretion on lease liabilities	3	2	3	5
Refund (payment) of income taxes		(426)	830	(2,067)
Other asset		(25)		(107)
Changes in operating assets and liabilities (note 9)	168	1,344	254	2,410
Net cash used in operating activities	(3,945)	(1,488)	(10,256)	(6,168)
Cash flows from financing activities
Issuance of common shares (note 8)				34,200
Transaction costs (note 8)				(3,221)
Proceeds from exercise of warrants (note 8)				20,042
Payments on lease liabilities	(33)	(31)	(101)	(95)
Net cash provided by (used in) financing activities	(33)	(31)	(101)	50,926
Cash flows from investing activities
Proceeds from disposal of property, plant and equipment				1
Purchase of intangible assets				(490)
Purchase of property and equipment	(9)	(5)	(57)	(25)
Change in restricted cash equivalents	4	(20)	4	(20)
Net cash used in investing activities	(5)	(25)	(53)	(534)
Effect of exchange rate changes on cash and cash equivalents	(358)	(322)	(1,074)	(493)
Net change in cash and cash equivalents	(4,341)	(1,866)	(11,484)	43,731
Cash and cash equivalents – Beginning of period	58,157	69,868	65,300	24,271
Cash and cash equivalents – End of period	$ 53,816	$ 68,002	$ 53,816	$ 68,002

Business overview

Business overview	9 Months Ended
	Sep. 30, 2022
Disclosure of detailed information about business combination [abstract]
Business overview	1. Business overview Summary of business Aeterna Zentaris (the “Company” or “Aeterna”) is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. Food and Drug Administration (“FDA”) and European Medicines Agency-approved oral test indicated for the diagnosis of patients with adult growth hormone deficiency (“AGHD”). Macrilen™ is currently marketed in the US through a license agreement (the “Novo Amendment”) between the Company and Novo Nordisk Health Care AG (“Novo”) and in the United Kingdom and Europe through a license agreement with Consilient Healthcare Inc (“Consilient” or “CH”) under the trade name of Ghryvelin®. The Company is also dedicated to the development of therapeutic assets and has recently taken steps to establish a pre-clinical pipeline to potentially address unmet medical needs across several indications with a focus on rare or orphan indications and with the potential for pediatric use. These unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the “Board”) on November 2, 2022. Basis of presentation These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”) applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting. These unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s annual consolidated financial statements as at and for the year ended December 31, 2021. The accounting policies used in these condensed interim consolidated financial statements are consistent with those presented in the Company’s annual consolidated financial statements, with the addition of the Company’s policy with respect to the government assistance which is as follows: Government assistance Amounts received or receivable resulting from government assistance programs, including grants and refundable investment tax credits for research and development, are accounted for in accordance with IAS 20 - Accounting for government grants and disclosure of government assistance COVID-19 & Russia and Ukraine conflict The rise in COVID-19 variants has caused delays in site initiation and patient enrollment in our DETECT-trial and may be impacting sales activities for Macrilen™ in the US. Further, the continuation of the COVID-19 pandemic and the Russia/Ukraine conflict may also cause some patients to be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if such events impede patient movement or interrupt healthcare services, both of which would delay our ability to conduct clinical trials or release clinical trial results on a timely basis and could delay our ability to obtain regulatory approval and commercialize our product candidates. For the period ended September 30, 2022, the Company assessed the impact of the uncertainties around the COVID-19 pandemic and the Russia/Ukraine conflict on its judgments, estimates, accounting policies and amounts recognized in these unaudited condensed interim consolidated financial statements and determined that no adjustments were required to the carrying value of assets and liabilities. During the quarter ended June 30, 2022, management determined that the recruitment for the DETECT-trial and the remaining development services under the Novo Amendment may now continue until later into 2023 compared to the end of the 2022 year as anticipated at the end of the previous fiscal year. It is expected that the delays associated with COVID-19 and the Russia/Ukraine conflict will result in additional costs to the program. As such, this change in estimate resulted in reversal of revenue in both the license fees and development services for the quarter ended June 30, 2022. During the quarter ended September 30, 2022, Novo provided the Company with a notice of termination of the Novo Amendment. Refer to note 3 for further details on the Novo Amendment. The Company will continue to monitor the impact of the development of the COVID-19 pandemic and Russia/Ukraine conflict in further reporting periods. Actual results could differ from these estimates, and such differences may be material. NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2022 AND FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) Restatement of comparative period figures At the end of the prior fiscal year 2021, the Company restated its previously reported condensed consolidated interim financial statements for the three-month period ended March 31, 2021 and the three-month and six-month periods ended June 30, 2021 and three-month and nine-month periods ended September 30, 2021 with respect to the recognition of revenue for the Novo Amendment, signed in November 2020. During the fourth quarter of 2021, management reassessed the classification of the development activities associated with the DETECT-trial and concluded that subsequent to the Novo Amendment, the parties no longer shared joint control of these activities and, as such, these development activities no longer met the definition of a joint operation, as defined in IFRS 11 - IFRS 15 - Revenue from Contracts with Customers Summary of Detailed Information about Restatement Explanatory Previously Effect of reported restatement Amended $ $ $ Consolidated interim statement of loss and comprehensive loss for the three-month period ended September 30, 2021 License fees 527 (234 ) 293 Development service revenues — 684 684 Research and development expenses 801 684 1,485 Net loss (1,698 ) (234 ) (1,932 ) Total comprehensive loss (1,440 ) (234 ) (1,674 ) Basic and diluted loss per share (0.35 ) (0.05 ) (0.40 ) Consolidated interim statement of loss and comprehensive loss for the nine-month period ended September 30, 2021 License fees 1,601 (292 ) 1,309 Development service revenues — 2,809 2,809 Research and development expenses 1,902 2,809 4,711 Net loss (5,182 ) (292 ) (5,474 ) Total comprehensive loss (4,589 ) (292 ) (4,881 ) Basic and diluted loss per share (1.07 ) (0.06 ) (1.21 ) Consolidated interim statement of financial position as of September 30, 2021 Prepaid expenses and other current assets 3,431 600 4,031 Current portion of deferred revenues 2,075 943 3,018 Deficit (327,708 ) (292 ) (328,000 )

Critical accounting estimates a

Critical accounting estimates and judgements	9 Months Ended
	Sep. 30, 2022
Critical accounting estimates and judgements	2. Critical accounting estimates and judgements The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgments, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared. Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgments in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgments used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as at and for the years ended December 31, 2021 and December 31, 2020. NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2022 AND FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted)

License and supply arrangements

License and supply arrangements	9 Months Ended
	Sep. 30, 2022
License And Supply Arrangements
License and supply arrangements	3. License and supply arrangements Novo Nordisk Health Care AG On November 16, 2020, the Company, through AEZS Germany, entered into the Novo Amendment of its existing License Agreement with Novo related to the development and commercialization of macimorelin. The Company earns product sales, royalties and supply chain revenue, in addition to license fees and development service revenue from conducting the DETECT-trial, from Novo. On August 26, 2022, Novo provided the Company with a notice of termination of the Novo Amendment. Under the terms of the Novo Amendment, the termination is effective May 23, 2023 upon the completion of a 270 day notice period (“notice period”). Upon termination, the rights and licenses granted by the Company to Novo under the Novo Amendment are returned to the Company, and the Company has full rights to continue the clinical development and future commercialization of Macrilen™. Following the notice of termination and throughout the 270 day notice period, Novo will continue to fund all DETECT-trial costs up to $ 8.6 9 8.6 9 9.2 9.8 The Company concluded that the notice of termination represents a contract modification for accounting purposes. The Company further concluded that upon receipt of the notice of termination, the remaining goods and services to be performed during the notice period are considered distinct goods and services and therefore, the contract modification is to be accounted for prospectively. As of the date of receipt of the notice of termination from Novo, the Company had recognized total license fees associated with the Pediatric Indication of $ 1,615 1,880 3,865 4,448 7,937 7,776 2,872 2,814 5,065 4,962 MegaPharm Ltd In June 2020, the Company entered into an exclusive distribution and quality agreement with MegaPharm Ltd. (“MegaPharm”) for the commercialization in Israel and in the Palestinian Authority of macimorelin to be used in the diagnosis of patients with adult growth hormone deficiency and in clinical development for the diagnosis of pediatric growth hormone deficiency (the “MegaPharm Agreement”). As of September 30, 2022, there have been no products supplied under this agreement. Consilient Healthcare On December 7, 2020, the Company entered into an exclusive licensing agreement with “CH” for the commercialization of macimorelin in the European Economic Area and the United Kingdom (the “CH License Agreement”). The Company earns licenses fees and product sale revenue from CH. NK Meditech Limited The Company and NK Meditech Limited (“NK”) entered into a licensing agreement, effective November 30, 2021 and pursuant to which the Company granted to NK the exclusive right to commercialize (including marketing, selling and offering to sell) macimorelin in the Republic of Korea (the “ROK”) and as applicable, in the Democratic People’s Republic of Korea (“DPRK”) to the extent NK is allowed to use the aforementioned licensed rights in the latter (“NK License Agreement”). As of September 30, 2022, there have been no products supplied under this agreement. The following table provides a summary of deferred revenue balances: Summary of Revenue Explanatory September 30, 2022 Current Non-Current Total $ $ $ Novo Amendment 3,466 — 3,466 CH License Agreement 18 1,345 1,363 NK License Agreement — 117 117 Total 3,484 1,462 4,946 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2022 AND FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) December 31, 2021 Current Non-Current Total $ $ $ Novo Amendment 4,791 23 4,814 CH License Agreement 24 1,334 1,358 NK License Agreement — 136 136 Total 4,815 1,493 6,308

Trade and other receivables

Trade and other receivables	9 Months Ended
	Sep. 30, 2022
Trade and other receivables	4. Trade and other receivables Summary of Detailed Trade and Other Receivables Explanatory September 30, 2022 December 31, 2021 $ $ Trade accounts receivable (net of expected credit losses of $ 55 55 383 877 Value-added tax 162 372 Grant receivable 201 — Other 31 65 Trade and other receivables 777 1,314 In March 2022, the Company was awarded a monetary subsidy with respect to two pre-clinical programs—namely, the Company’s development of an oral vaccine against infections with SARS-CoV-2 and the development of a product candidate for the treatment of neuromyelitis optica. The subsidy was awarded pursuant to the provisions of the German Act on Tax Incentives for Research and Development, which provides direct reimbursement of certain qualifying R&D expenditures to eligible entities. The CoV-2 grant is related to R&D expenditures incurred in 2021 and during 2022. The Neuromyelitis Optica grant is related to expenditures incurred in 2021 and during 2022.

Prepaid expenses and other curr

Prepaid expenses and other current assets	9 Months Ended
	Sep. 30, 2022
Prepaid expenses and other current assets	5. Prepaid expenses and other current assets Summary of Prepaid Expenses and Other Current Assets Explanatory September 30, 2022 December 31, 2021 $ $ Prepaid insurance 839 421 Prepaid research and development 1,561 1,329 Other 74 22 Prepaid expenses and other current assets 2,474 1,772 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2022 AND FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted)

Payables and accrued liabilitie

Payables and accrued liabilities	9 Months Ended
	Sep. 30, 2022
Payables and accrued liabilities	6. Payables and accrued liabilities Summary of Detailed Information about Payables and Accrued Liabilities Explanatory September 30, 2022 December 31, 2021 $ $ Trade accounts payable 720 934 Salaries, employment taxes and benefits 89 531 Accrued research and development costs 855 596 Other accrued liabilities 623 611 Payables and accrued liabilities 2,287 2,672

Employee future benefits

Employee future benefits	9 Months Ended
	Sep. 30, 2022
Employee future benefits	7. Employee future benefits The change in the Company’s accrued benefit obligations is summarized as follows: Summary of Net Defined Benefit Liability Asset Explanatory Nine months ended September 30, 2022 Year ended December 31, 2021 Pension Other benefit plans benefit plans Total Total $ $ $ $ Change in plan liabilities Balances – Beginning of the period 29,313 99 29,412 15,435 Current service cost 48 8 56 65 Interest cost 209 1 210 88 Employee contributions 10 — 10 — Actuarial gain arising from changes in financial assumptions (8,528 ) — (8,528 ) (1,130 ) Past service cost associated with multi-employer plan — — — 16,137 Actuarial loss arising from change in current assumptions on funding of future pension increases — — — 556 Benefits paid (513 ) (1 ) (514 ) (511 ) Impact of foreign exchange rate changes (3,032 ) (14 ) (3,046 ) (1,228 ) Balances – End of the period 17,507 93 17,600 29,412 Change in plan assets Balances – Beginning of the period 11,927 — 11,927 — Presentation of plan assets as of December 31, 2021 — — — 11,963 Remeasurement of plan assets (2,297 ) — (2,297 ) — Employer contributions 40 — 40 — Employee contributions 10 — 10 — Benefits paid (182 ) — (182 ) — Impact of foreign exchange rate changes (1,356 ) — (1,356 ) (36 ) Balances – End of the period 8,142 — 8,142 11,927 Net liability of the unfunded plans 8,170 93 8,263 12,749 Net liability of the funded plans 1,195 — 1,195 4,736 Net amount recognized as Employee future benefits 9,365 93 9,458 17,485 Amounts recognized: In net loss 257 9 266 (153 ) In other comprehensive (gain) loss (7,907 ) (14 ) (7,921 ) (2,408 ) The calculation of the pension benefit obligation is sensitive to the discount rate assumption and other assumptions such as the rate of the pension benefit increase. Discount rates were 1.1% 3.25% 3.70% 0.50% 1.0% NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2022 AND FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted)

Share capital, warrants and oth

Share capital, warrants and other capital	9 Months Ended
	Sep. 30, 2022
Disclosure of classes of share capital [abstract]
Share capital, warrants and other capital	8. Share capital, warrants and other capital The Company has an unlimited number of authorized common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value. On July 15, 2022, the Company’s shareholders and board of directors approved an amendment to the Company’s articles of amendment to effect a 1-for-25 reverse stock split of the Company’s common shares, DSU and Warrants. The Company’s outstanding stock options were also adjusted to reflect the 1-for-25 reverse stock split of the Company’s common shares. Accordingly, all common shares, DSU and Warrants, stock options and per share amounts in these condensed interim consolidated financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split was effected in the markets on July 21, 2022. 2021 On February 19, 2021, the Company completed an underwritten public offering of 820,390 36.25 29,739 2,837 123,058 36.25 57,427 45.31 February 17, 2026 On February 22, 2021, the underwriter exercised the Underwriter Option in full and received 123,058 4,461 8,614 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2022 AND FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) Aggregate gross proceeds received in connection with the February 2021 Financing totaled $ 34,200 3,221 1,897 The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of these Placement agent warrants: Summary of Fair Value of Warrants Assumptions Explanatory Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield ($) ($) (i) (ii) (iii) (iv) February 2021 Placement agent warrants – public offering 57,427 37 45.31 0.59 % 119.18 % 4.99 0 % February 2021 Placement agent warrants – Underwriter Option 8,614 37 45.31 0.59 % 119.57 % 4.98 0 % (i) During the nine-month period ended September 30, 2021, warrants were exercised as follows: (ii) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (iii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants. (iv) Based upon time to expiry from the issuance date. During the nine-month period ended September 30, 2021, warrants were exercised as follows: Summary of Warrants Exercise Transactions Explanatory Warrants exercised (number of underlying common shares) Exercise Price Aggregate proceeds to the Company Warrants exercised (number of underlying common shares) Exercise Price Aggregate proceeds to the Company September 2019 Investor warrants 80,000 $ 41.25 $ 3,300 February 2020 Investor warrants 69,565 30.00 2,087 July 2020 Investor warrants 841,822 11.25 9,471 July 2020 Placement Agent warrants 74,667 14.06 1,050 August 2020 Investor warrants 303,595 11.75 3,567 August 2020 Placement Agent warrants 34,798 17.60 612 1,404,447 $ 20,087 Other capital Summary of Number and Weighted Average Exercise Prices of Share Options Explanatory Nine months ended September 30, 2022 Stock options Weighted average exercise DSUs (Number) ($) (Number) Balance – January 1, 2022 43,455 22.00 16,920 Granted 2,000 8.88 80,000 Expired — — — Exercised — — — Balance – September 30, 2022 45,455 21.42 96,920 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2022 AND FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) Year ended December 31, 2021 Stock options Weighted average exercise price DSUs (Number) ($) (Number) Balance – January 1, 2021 20,256 36 6,920 Granted 23,200 10.5 11,200 Expired (1 ) 14,756.25 — Exercised — — (1,200 ) Balance – December 31, 2021 43,455 22 16,920 The DSU compensation expense for the three months ended September 30, 2022 was $ 402 nil 402 244 Fair value input assumptions for US dollar stock option grants The table below shows the assumptions, or weighted average parameters, applied to the Black-Scholes option pricing model in order to determine share-based compensation costs over the life of the awards. Summary of Assumptions to Determine Share-based Compensation Costs Nine Months Ended Year Ended September 30, December 31, 2022 2021 Expected dividend yield (a) 0.00 % 0.00 % Expected volatility (b) 115.75 % 115.80 % Risk-free annual interest rate (c) 1.59 % 1.23 % Expected life (years) (d) 5.72 5.71 Weighted average share price $ 8.88 $ 10.50 Weighted average exercise price $ 8.88 $ 10.50 Weighted average grant date fair value $ 7.47 $ 8.82 (a) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. (b) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations. (c) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options. (d) Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.

Supplemental disclosure of cash

Supplemental disclosure of cash flow information	9 Months Ended
	Sep. 30, 2022
Supplemental disclosure of cash flow information	9. Supplemental disclosure of cash flow information Summary of Changes in Operating Assets and Liabilities Explanatory Three months ended Nine months ended September 30, 2022 September 30, 2022 2022 2021 2022 2021 $ $ $ $ Changes in operating assets and liabilities: Trade and other receivables 205 563 425 666 Inventory 41 — (165 ) (39 ) Prepaid expenses and other current assets (481 ) 233 (1,240 ) 548 Payables and accrued liabilities (133 ) 298 (14 ) (17 ) Taxes payable 210 — 210 (129 ) Deferred revenues 595 318 1,425 1,606 Employee future benefits (269 ) (68 ) (387 ) (225 ) Changes in operating assets and liabilities 168 1,344 254 2,410 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2022 AND FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted)

Segment information

Segment information	9 Months Ended
	Sep. 30, 2022
Segment information	10. Segment information The Company operates in a single operating segment, being the biopharmaceutical segment.

Net loss per share

Net loss per share	9 Months Ended
	Sep. 30, 2022
Net loss per share	11. Net loss per share The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Summary of Earnings per Share Explanatory $ $ $ $ Three months ended Nine months ended September 30, September 20, 2022 2021 2022 2021 $ $ $ $ Net loss (3,420 ) (1,932 ) (10,276 ) (5,474 ) Basic weighted average number of shares outstanding 4,855,876 4,851,880 4,855,876 4,509,731 Net loss income per share (basic) (0.70 ) (0.40 ) (2.12 ) (1.21 ) Dilutive effect of stock options and DSUs — — — — Dilutive effect of warrants — — — — Diluted weighted average number of shares outstanding 4,855,876 4,851,880 4,855,876 4,509,731 Net loss per share (diluted) (0.70 ) 0.40 (2.12 ) (1.21 ) Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect Stock options and DSUs 142,375 37,176 142,375 37,176 Warrants 457,649 461,649 457,649 461,649 Net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during the relevant period. Diluted weighted average number of shares reflects the dilutive effect of equity instruments, such as any “in the money” stock options, DSUs and warrants. In periods with reported net losses, all stock options and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal, and thus “in the money” stock options and warrants have not been included in the computation of net loss per share because to do so would be anti-dilutive.

Commitments

Commitments	9 Months Ended
	Sep. 30, 2022
Commitments	12. Commitments Summary of Finance Lease and Operating Lease by Lessee Explanatory Service and manufacturing R&D contracts TOTAL $ $ $ Less than 1 year 7,006 1,870 8,876 1 - 3 years 2,089 629 2,718 4 - 5 years 46 — 46 More than 5 years — — — Total 9,141 2,499 11,640 The Company executed various agreements including in-licensing and similar arrangements with development partners. Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty. Based on the closing exchange rates at September 30, 2022, the Company expects to pay $ 8,527 6.5 1.2 37,438 27.6 1.3 9,000 Summary of Research and Development and Revenue Related Milestone Payments Explanatory Future potential R&D milestone payments Future potential revenue milestone payments TOTAL $ $ $ Less than 1 year 24 — 24 1 - 3 years 198 — 198 4 - 5 years 1,243 — 1,243 More than 5 years 7,062 37,438 44,500 Total 8,527 37,438 45,965 The future payments that are disclosed represent contract payments and are not discounted and are not risk-adjusted. The development of any pharmaceutical product candidates is a complex and risky process that may fail at any stage in the development process due to a number of factors. The timing of the payments is based on the Company’s current best estimate of achievement of the relevant milestone.

Business overview (Tables)

Business overview (Tables)	9 Months Ended
	Sep. 30, 2022
Disclosure of detailed information about business combination [abstract]
Summary of Detailed Information about Restatement Explanatory	Summary of Detailed Information about Restatement Explanatory Previously Effect of reported restatement Amended $ $ $ Consolidated interim statement of loss and comprehensive loss for the three-month period ended September 30, 2021 License fees 527 (234 ) 293 Development service revenues — 684 684 Research and development expenses 801 684 1,485 Net loss (1,698 ) (234 ) (1,932 ) Total comprehensive loss (1,440 ) (234 ) (1,674 ) Basic and diluted loss per share (0.35 ) (0.05 ) (0.40 ) Consolidated interim statement of loss and comprehensive loss for the nine-month period ended September 30, 2021 License fees 1,601 (292 ) 1,309 Development service revenues — 2,809 2,809 Research and development expenses 1,902 2,809 4,711 Net loss (5,182 ) (292 ) (5,474 ) Total comprehensive loss (4,589 ) (292 ) (4,881 ) Basic and diluted loss per share (1.07 ) (0.06 ) (1.21 ) Consolidated interim statement of financial position as of September 30, 2021 Prepaid expenses and other current assets 3,431 600 4,031 Current portion of deferred revenues 2,075 943 3,018 Deficit (327,708 ) (292 ) (328,000 )

License and supply arrangemen_2

License and supply arrangements (Tables)	9 Months Ended
	Sep. 30, 2022
License And Supply Arrangements
Summary of Revenue Explanatory	The following table provides a summary of deferred revenue balances: Summary of Revenue Explanatory September 30, 2022 Current Non-Current Total $ $ $ Novo Amendment 3,466 — 3,466 CH License Agreement 18 1,345 1,363 NK License Agreement — 117 117 Total 3,484 1,462 4,946 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2022 AND FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) December 31, 2021 Current Non-Current Total $ $ $ Novo Amendment 4,791 23 4,814 CH License Agreement 24 1,334 1,358 NK License Agreement — 136 136 Total 4,815 1,493 6,308

Trade and other receivables (Ta

Trade and other receivables (Tables)	9 Months Ended
	Sep. 30, 2022
Summary of Detailed Trade and Other Receivables Explanatory	Summary of Detailed Trade and Other Receivables Explanatory September 30, 2022 December 31, 2021 $ $ Trade accounts receivable (net of expected credit losses of $ 55 55 383 877 Value-added tax 162 372 Grant receivable 201 — Other 31 65 Trade and other receivables 777 1,314

Prepaid expenses and other cu_2

Prepaid expenses and other current assets (Tables)	9 Months Ended
	Sep. 30, 2022
Summary of Prepaid Expenses and Other Current Assets Explanatory	Summary of Prepaid Expenses and Other Current Assets Explanatory September 30, 2022 December 31, 2021 $ $ Prepaid insurance 839 421 Prepaid research and development 1,561 1,329 Other 74 22 Prepaid expenses and other current assets 2,474 1,772

Payables and accrued liabilit_2

Payables and accrued liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Summary of Detailed Information about Payables and Accrued Liabilities Explanatory	Summary of Detailed Information about Payables and Accrued Liabilities Explanatory September 30, 2022 December 31, 2021 $ $ Trade accounts payable 720 934 Salaries, employment taxes and benefits 89 531 Accrued research and development costs 855 596 Other accrued liabilities 623 611 Payables and accrued liabilities 2,287 2,672

Employee future benefits (Table

Employee future benefits (Tables)	9 Months Ended
	Sep. 30, 2022
Summary of Net Defined Benefit Liability Asset Explanatory	The change in the Company’s accrued benefit obligations is summarized as follows: Summary of Net Defined Benefit Liability Asset Explanatory Nine months ended September 30, 2022 Year ended December 31, 2021 Pension Other benefit plans benefit plans Total Total $ $ $ $ Change in plan liabilities Balances – Beginning of the period 29,313 99 29,412 15,435 Current service cost 48 8 56 65 Interest cost 209 1 210 88 Employee contributions 10 — 10 — Actuarial gain arising from changes in financial assumptions (8,528 ) — (8,528 ) (1,130 ) Past service cost associated with multi-employer plan — — — 16,137 Actuarial loss arising from change in current assumptions on funding of future pension increases — — — 556 Benefits paid (513 ) (1 ) (514 ) (511 ) Impact of foreign exchange rate changes (3,032 ) (14 ) (3,046 ) (1,228 ) Balances – End of the period 17,507 93 17,600 29,412 Change in plan assets Balances – Beginning of the period 11,927 — 11,927 — Presentation of plan assets as of December 31, 2021 — — — 11,963 Remeasurement of plan assets (2,297 ) — (2,297 ) — Employer contributions 40 — 40 — Employee contributions 10 — 10 — Benefits paid (182 ) — (182 ) — Impact of foreign exchange rate changes (1,356 ) — (1,356 ) (36 ) Balances – End of the period 8,142 — 8,142 11,927 Net liability of the unfunded plans 8,170 93 8,263 12,749 Net liability of the funded plans 1,195 — 1,195 4,736 Net amount recognized as Employee future benefits 9,365 93 9,458 17,485 Amounts recognized: In net loss 257 9 266 (153 ) In other comprehensive (gain) loss (7,907 ) (14 ) (7,921 ) (2,408 )

Share capital, warrants and o_2

Share capital, warrants and other capital (Tables)	9 Months Ended
	Sep. 30, 2022
Disclosure of classes of share capital [abstract]
Summary of Fair Value of Warrants Assumptions Explanatory	The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of these Placement agent warrants: Summary of Fair Value of Warrants Assumptions Explanatory Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield ($) ($) (i) (ii) (iii) (iv) February 2021 Placement agent warrants – public offering 57,427 37 45.31 0.59 % 119.18 % 4.99 0 % February 2021 Placement agent warrants – Underwriter Option 8,614 37 45.31 0.59 % 119.57 % 4.98 0 % (i) During the nine-month period ended September 30, 2021, warrants were exercised as follows: (ii) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (iii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants. (iv) Based upon time to expiry from the issuance date.
Summary of Warrants Exercise Transactions Explanatory	During the nine-month period ended September 30, 2021, warrants were exercised as follows: Summary of Warrants Exercise Transactions Explanatory Warrants exercised (number of underlying common shares) Exercise Price Aggregate proceeds to the Company Warrants exercised (number of underlying common shares) Exercise Price Aggregate proceeds to the Company September 2019 Investor warrants 80,000 $ 41.25 $ 3,300 February 2020 Investor warrants 69,565 30.00 2,087 July 2020 Investor warrants 841,822 11.25 9,471 July 2020 Placement Agent warrants 74,667 14.06 1,050 August 2020 Investor warrants 303,595 11.75 3,567 August 2020 Placement Agent warrants 34,798 17.60 612 1,404,447 $ 20,087
Summary of Number and Weighted Average Exercise Prices of Share Options Explanatory	Summary of Number and Weighted Average Exercise Prices of Share Options Explanatory Nine months ended September 30, 2022 Stock options Weighted average exercise DSUs (Number) ($) (Number) Balance – January 1, 2022 43,455 22.00 16,920 Granted 2,000 8.88 80,000 Expired — — — Exercised — — — Balance – September 30, 2022 45,455 21.42 96,920 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2022 AND FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) Year ended December 31, 2021 Stock options Weighted average exercise price DSUs (Number) ($) (Number) Balance – January 1, 2021 20,256 36 6,920 Granted 23,200 10.5 11,200 Expired (1 ) 14,756.25 — Exercised — — (1,200 ) Balance – December 31, 2021 43,455 22 16,920
Summary of Assumptions to Determine Share-based Compensation Costs	The table below shows the assumptions, or weighted average parameters, applied to the Black-Scholes option pricing model in order to determine share-based compensation costs over the life of the awards. Summary of Assumptions to Determine Share-based Compensation Costs Nine Months Ended Year Ended September 30, December 31, 2022 2021 Expected dividend yield (a) 0.00 % 0.00 % Expected volatility (b) 115.75 % 115.80 % Risk-free annual interest rate (c) 1.59 % 1.23 % Expected life (years) (d) 5.72 5.71 Weighted average share price $ 8.88 $ 10.50 Weighted average exercise price $ 8.88 $ 10.50 Weighted average grant date fair value $ 7.47 $ 8.82 (a) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. (b) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations. (c) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options. (d) Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.

Supplemental disclosure of ca_2

Supplemental disclosure of cash flow information (Tables)	9 Months Ended
	Sep. 30, 2022
Summary of Changes in Operating Assets and Liabilities Explanatory	Summary of Changes in Operating Assets and Liabilities Explanatory Three months ended Nine months ended September 30, 2022 September 30, 2022 2022 2021 2022 2021 $ $ $ $ Changes in operating assets and liabilities: Trade and other receivables 205 563 425 666 Inventory 41 — (165 ) (39 ) Prepaid expenses and other current assets (481 ) 233 (1,240 ) 548 Payables and accrued liabilities (133 ) 298 (14 ) (17 ) Taxes payable 210 — 210 (129 ) Deferred revenues 595 318 1,425 1,606 Employee future benefits (269 ) (68 ) (387 ) (225 ) Changes in operating assets and liabilities 168 1,344 254 2,410

Net loss per share (Tables)

Net loss per share (Tables)	9 Months Ended
	Sep. 30, 2022
Summary of Earnings per Share Explanatory	The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Summary of Earnings per Share Explanatory $ $ $ $ Three months ended Nine months ended September 30, September 20, 2022 2021 2022 2021 $ $ $ $ Net loss (3,420 ) (1,932 ) (10,276 ) (5,474 ) Basic weighted average number of shares outstanding 4,855,876 4,851,880 4,855,876 4,509,731 Net loss income per share (basic) (0.70 ) (0.40 ) (2.12 ) (1.21 ) Dilutive effect of stock options and DSUs — — — — Dilutive effect of warrants — — — — Diluted weighted average number of shares outstanding 4,855,876 4,851,880 4,855,876 4,509,731 Net loss per share (diluted) (0.70 ) 0.40 (2.12 ) (1.21 ) Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect Stock options and DSUs 142,375 37,176 142,375 37,176 Warrants 457,649 461,649 457,649 461,649

Commitments (Tables)

Commitments (Tables)	9 Months Ended
	Sep. 30, 2022
Summary of Finance Lease and Operating Lease by Lessee Explanatory	Summary of Finance Lease and Operating Lease by Lessee Explanatory Service and manufacturing R&D contracts TOTAL $ $ $ Less than 1 year 7,006 1,870 8,876 1 - 3 years 2,089 629 2,718 4 - 5 years 46 — 46 More than 5 years — — — Total 9,141 2,499 11,640
Summary of Research and Development and Revenue Related Milestone Payments Explanatory	Summary of Research and Development and Revenue Related Milestone Payments Explanatory Future potential R&D milestone payments Future potential revenue milestone payments TOTAL $ $ $ Less than 1 year 24 — 24 1 - 3 years 198 — 198 4 - 5 years 1,243 — 1,243 More than 5 years 7,062 37,438 44,500 Total 8,527 37,438 45,965

Summary of Detailed Information

Summary of Detailed Information about Restatement Explanatory (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
License fees	$ 605	$ 293	$ 831	$ 1,309
Development service revenues	1,202	684	2,091	2,809
Research and development expenses	3,293	1,485	8,081	4,711
Net loss	(3,420)	(1,932)	(10,276)	(5,474)
Total comprehensive loss	$ (5,319)	$ (1,674)	$ (4,071)	$ (4,881)
Basic and diluted loss per share	$ (0.70)	$ (0.40)	$ (2.12)	$ (1.21)
Prepaid expenses and other current assets	$ 2,474	$ 4,031	$ 2,474	$ 4,031	$ 1,772
Current portion of deferred revenues	3,484	3,018	3,484	3,018	4,815
Deficit	$ (338,664)	(328,000)	$ (338,664)	(328,000)	$ (334,619)
Previously stated [member]
IfrsStatementLineItems [Line Items]
License fees		527		1,601
Development service revenues
Research and development expenses		801		1,902
Net loss		(1,698)		(5,182)
Total comprehensive loss		$ (1,440)		$ (4,589)
Basic and diluted loss per share		$ (0.35)		$ (1.07)
Prepaid expenses and other current assets		$ 3,431		$ 3,431
Current portion of deferred revenues		2,075		2,075
Deficit		(327,708)		(327,708)
Increase (decrease) due to corrections of prior period errors [member]
IfrsStatementLineItems [Line Items]
License fees		(234)		(292)
Development service revenues		684		2,809
Research and development expenses		684		2,809
Net loss		(234)		(292)
Total comprehensive loss		$ (234)		$ (292)
Basic and diluted loss per share		$ (0.05)		$ (0.06)
Prepaid expenses and other current assets		$ 600		$ 600
Current portion of deferred revenues		943		943
Deficit		$ (292)		$ (292)

Summary of Revenue Explanatory

Summary of Revenue Explanatory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
IfrsStatementLineItems [Line Items]
Total Deferred Revenues Current	$ 3,484	$ 4,815	$ 3,018
Total Deferred Revenues Non Current	1,462	1,493
Total Deferred Revenues	4,946	6,308
Novo Amendment [member]
IfrsStatementLineItems [Line Items]
Total Deferred Revenues Current	3,466	4,791
Total Deferred Revenues Non Current		23
Total Deferred Revenues	3,466	4,814
CH License Agreement [member]
IfrsStatementLineItems [Line Items]
Total Deferred Revenues Current	18	24
Total Deferred Revenues Non Current	1,345	1,334
Total Deferred Revenues	1,363	1,358
NK License Agreement [member]
IfrsStatementLineItems [Line Items]
Total Deferred Revenues Current
Total Deferred Revenues Non Current	117	136
Total Deferred Revenues	$ 117	$ 136

License and supply arrangemen_3

License and supply arrangements (Details Narrative)					3 Months Ended		9 Months Ended
	Aug. 27, 2022 USD ($)	Aug. 27, 2022 EUR (€)	Aug. 26, 2022 USD ($)	Aug. 26, 2022 EUR (€)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Aug. 27, 2022 EUR (€)
IfrsStatementLineItems [Line Items]
Licenses fees					$ 605,000	$ 293,000	$ 831,000	$ 1,309,000
Top of range [member]
IfrsStatementLineItems [Line Items]
Proceeds from amendment funds			$ 9,200,000	€ 9,800,000
Novo Nordisk Health Care AG [member]
IfrsStatementLineItems [Line Items]
Licenses fees	$ 2,872,000	€ 2,814,000	1,615,000	1,880,000
Revenue from development services	5,065	€ 4,962	3,865	4,448
Transaction costs	$ 7,937,000								€ 7,776
Novo Nordisk Health Care AG [member] | Top of range [member]
IfrsStatementLineItems [Line Items]
Proceeds from amendment funds			$ 8,600,000	€ 9,000,000

Summary of Detailed Trade and O

Summary of Detailed Trade and Other Receivables Explanatory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Trade accounts receivable (net of expected credit losses of $55 (December 31, 2021 – $55)	$ 383	$ 877
Value-added tax	162	372
Grant receivable	201
Other	31	65
Trade and other receivables	$ 777	$ 1,314

Summary of Detailed Trade and_2

Summary of Detailed Trade and Other Receivables Explanatory (Details) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Trade accounts receivable, expected credit losses	$ 55	$ 55

Summary of Prepaid Expenses and

Summary of Prepaid Expenses and Other Current Assets Explanatory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Prepaid insurance	$ 839	$ 421
Prepaid research and development	1,561	1,329
Other	74	22
Prepaid expenses and other current assets	$ 2,474	$ 1,772	$ 4,031

Summary of Detailed Informati_2

Summary of Detailed Information about Payables and Accrued Liabilities Explanatory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Trade accounts payable	$ 720	$ 934
Salaries, employment taxes and benefits	89	531
Accrued research and development costs	855	596
Other accrued liabilities	623	611
Payables and accrued liabilities	$ 2,287	$ 2,672

Summary of Net Defined Benefit

Summary of Net Defined Benefit Liability Asset Explanatory (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Change in plan liabilities
Balances – Beginning of the period	$ 29,412	$ 15,435
Current service cost	56	65
Interest cost	210	88
Employee contributions	10
Actuarial gain arising from changes in financial assumptions	(8,528)	(1,130)
Past service cost associated with multi-employer plan		16,137
Actuarial loss arising from change in current assumptions on funding of future pension increases		556
Benefits paid	(514)	(511)
Impact of foreign exchange rate changes	(3,046)	(1,228)
Balances – End of the period	17,600	29,412
Change in plan assets
Balances – Beginning of the period	11,927
Presentation of plan assets as of December 31, 2021		11,963
Remeasurement of plan assets	(2,297)
Employer contributions	40
Employee contributions	10
Benefits paid	(182)
Impact of foreign exchange rate changes	(1,356)	(36)
Balances – End of the period	8,142	11,927
Net liability of the unfunded plans	8,263	12,749
Net liability of the funded plans	1,195	4,736
Net amount recognized as Employee future benefits	9,458	17,485
Amounts recognized:
In net loss	266	(153)
In other comprehensive (gain) loss	(7,921)	(2,408)
Pension defined benefit plans [member]
Change in plan liabilities
Balances – Beginning of the period	29,313
Current service cost	48
Interest cost	209
Employee contributions	10
Actuarial gain arising from changes in financial assumptions	(8,528)
Past service cost associated with multi-employer plan
Actuarial loss arising from change in current assumptions on funding of future pension increases
Benefits paid	(513)
Impact of foreign exchange rate changes	(3,032)
Balances – End of the period	17,507	29,313
Change in plan assets
Balances – Beginning of the period	11,927
Presentation of plan assets as of December 31, 2021
Remeasurement of plan assets	(2,297)
Employer contributions	40
Employee contributions	10
Benefits paid	(182)
Impact of foreign exchange rate changes	(1,356)
Balances – End of the period	8,142	11,927
Net liability of the unfunded plans	8,170
Net liability of the funded plans	1,195
Net amount recognized as Employee future benefits	9,365
Amounts recognized:
In net loss	257
In other comprehensive (gain) loss	(7,907)
Other Benefit Plans [member]
Change in plan liabilities
Balances – Beginning of the period	99
Current service cost	8
Interest cost	1
Employee contributions
Actuarial gain arising from changes in financial assumptions
Past service cost associated with multi-employer plan
Actuarial loss arising from change in current assumptions on funding of future pension increases
Benefits paid	(1)
Impact of foreign exchange rate changes	(14)
Balances – End of the period	93	99
Change in plan assets
Balances – Beginning of the period
Presentation of plan assets as of December 31, 2021
Remeasurement of plan assets
Employer contributions
Employee contributions
Benefits paid
Impact of foreign exchange rate changes
Balances – End of the period
Net liability of the unfunded plans	93
Net liability of the funded plans
Net amount recognized as Employee future benefits	93
Amounts recognized:
In net loss	9
In other comprehensive (gain) loss	$ (14)

Employee future benefits (Detai

Employee future benefits (Details Narrative) - Pension defined benefit plans [member]	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Defined benefit obligation, discount rate	3.70%	3.25%	1.10%
Pension benefits increase rates	1%	0.50%	0.50%

Summary of Fair Value of Warran

Summary of Fair Value of Warrants Assumptions Explanatory (Details) - $ / shares shares in Thousands		9 Months Ended	12 Months Ended
		Sep. 30, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Market value per share price		$ 8.88	$ 10.50
Risk-free annual interest rate	[1]	1.59%	1.23%
Expected volatility	[2]	115.75%	115.80%
Expected dividend yield	[3]	0%	0%
February 2021 Placement Agent Warrants Public Offering [member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares		57,427
Market value per share price		$ 37
Weighted average exercise price		$ 45.31
Expected volatility	[4]	119.18%
Expected life (years)	[5]	4 years 11 months 26 days
Expected dividend yield	[6]	0%
February 2021 Placement Agent Warrants Underwriter Option [member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares		8,614
Market value per share price		$ 37
Weighted average exercise price		$ 45.31
Risk-free annual interest rate	[7]	0.59%
Expected volatility	[4]	119.57%
Expected life (years)	[5]	4 years 11 months 23 days
Expected dividend yield	[6]	0%
[1]Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options.[2]Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations.[3]The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.[4]Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants.[5]Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants.[6]Based upon time to expiry from the issuance date.[7]During the nine-month period ended September 30, 2021, warrants were exercised as follows:

Summary of Warrants Exercise Tr

Summary of Warrants Exercise Transactions Explanatory (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($) shares $ / shares
IfrsStatementLineItems [Line Items]
Warrants exercised (number of underlying common shares) | shares	1,404,447
Aggregate proceeds to the Company | $	$ 20,087
September 2019 Investor Warrants [member]
IfrsStatementLineItems [Line Items]
Warrants exercised (number of underlying common shares) | shares	80,000
Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period | $ / shares	$ 41.25
Aggregate proceeds to the Company | $	$ 3,300
February 2020 Investor Warrants [member]
IfrsStatementLineItems [Line Items]
Warrants exercised (number of underlying common shares) | shares	69,565
Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period | $ / shares	$ 30
Aggregate proceeds to the Company | $	$ 2,087
July 2020 Investor Warrants [member]
IfrsStatementLineItems [Line Items]
Warrants exercised (number of underlying common shares) | shares	841,822
Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period | $ / shares	$ 11.25
Aggregate proceeds to the Company | $	$ 9,471
July 2020 Placement Agent Warrants [member]
IfrsStatementLineItems [Line Items]
Warrants exercised (number of underlying common shares) | shares	74,667
Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period | $ / shares	$ 14.06
Aggregate proceeds to the Company | $	$ 1,050
August 2020 Investor Warrants [member]
IfrsStatementLineItems [Line Items]
Warrants exercised (number of underlying common shares) | shares	303,595
Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period | $ / shares	$ 11.75
Aggregate proceeds to the Company | $	$ 3,567
August 2020 Placement Agent Warrants [member]
IfrsStatementLineItems [Line Items]
Warrants exercised (number of underlying common shares) | shares	34,798
Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period | $ / shares	$ 17.60
Aggregate proceeds to the Company | $	$ 612

Summary of Number and Weighted

Summary of Number and Weighted Average Exercise Prices of Share Options Explanatory (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares
IfrsStatementLineItems [Line Items]
Shares, exercised	(1,404,447)
Employee Stock Option USD [member]
IfrsStatementLineItems [Line Items]
Shares, balance beginning	43,455	20,256
Weighted average exercise price, balance beginning | $ / shares	$ 22	$ 36
Shares, granted	2,000	23,200
Weighted average exercise price, granted | $ / shares	$ 8.88	$ 10.5
Shares, expired		(1)
Weighted average exercise price, expired | $ / shares		$ 14,756.25
Shares, exercised
Weighted average exercise price, exercised | $ / shares
Shares, balance ending	45,455	43,455
Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period | $ / shares	$ 21.42	$ 22
Deferred Stock Units DSU [member]
IfrsStatementLineItems [Line Items]
Shares, balance beginning	16,920	6,920
Shares, granted	80,000	11,200
Shares, expired
Shares, exercised		(1,200)
Shares, balance ending	96,920	16,920

Summary of Assumptions to Deter

Summary of Assumptions to Determine Share-based Compensation Costs (Details) - $ / shares		9 Months Ended	12 Months Ended
		Sep. 30, 2022	Dec. 31, 2021
Disclosure of classes of share capital [abstract]
Expected dividend yield	[1]	0%	0%
Expected volatility	[2]	115.75%	115.80%
Risk-free annual interest rate	[3]	1.59%	1.23%
Expected life (years)	[4]	5 years 8 months 19 days	5 years 8 months 15 days
Weighted average share price		$ 8.88	$ 10.50
Weighted average exercise price		8.88	10.50
Weighted average grant date fair value		$ 7.47	$ 8.82
[1]The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.[2]Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations.[3]Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options.[4]Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.

Share capital, warrants and o_3

Share capital, warrants and other capital (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		9 Months Ended
	Feb. 22, 2021	Feb. 19, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
IfrsStatementLineItems [Line Items]
Cash transaction costs						$ (3,221)
Warrants [member]
IfrsStatementLineItems [Line Items]
Proceeds from issuing common shares	$ 34,200
Cash transaction costs	3,221
Warrant liability	$ 1,897
Underwriter Option [member]
IfrsStatementLineItems [Line Items]
Number of common shares issued, shares	8,614
Proceeds from issuing common shares	$ 4,461
Option to purchase common stock	123,058
Deferred Share Unit [Member]
IfrsStatementLineItems [Line Items]
Compensation expenses			$ 402		$ 402	$ 244
Public Offering [member]
IfrsStatementLineItems [Line Items]
Number of common shares issued, shares		820,390
Share price		$ 36.25
Proceeds from issuing common shares		$ 29,739
Placement agent fees and other offering expenses		$ 2,837
Public Offering [member] | Warrants [member]
IfrsStatementLineItems [Line Items]
Warrants Issued		57,427
Warrants exercise price		$ 45.31
Warrants expiry date		Feb. 17, 2026
Underwriter Option [member]
IfrsStatementLineItems [Line Items]
Share price		$ 36.25
Option to purchase common stock		123,058

Summary of Changes in Operating

Summary of Changes in Operating Assets and Liabilities Explanatory (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Changes in operating assets and liabilities:
Trade and other receivables	$ 205	$ 563	$ 425	$ 666
Inventory	41		(165)	(39)
Prepaid expenses and other current assets	(481)	233	(1,240)	548
Payables and accrued liabilities	(133)	298	(14)	(17)
Taxes payable	210		210	(129)
Deferred revenues	595	318	1,425	1,606
Employee future benefits	(269)	(68)	(387)	(225)
Changes in operating assets and liabilities	$ 168	$ 1,344	$ 254	$ 2,410

Summary of Earnings per Share E

Summary of Earnings per Share Explanatory (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net loss	$ (3,420)	$ (1,932)	$ (10,276)	$ (5,474)
Basic weighted average number of shares outstanding	4,855,876	4,851,880	4,855,876	4,509,731
Net loss income per share (basic)	$ (0.70)	$ (0.40)	$ (2.12)	$ (1.21)
Dilutive effect of stock options and DSUs
Dilutive effect of warrants
Diluted weighted average number of shares outstanding	4,855,876	4,851,880	4,855,876	4,509,731
Net loss per share (diluted)	$ (0.70)	$ 0.40	$ (2.12)	$ (1.21)
Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect
Stock options and DSUs	142,375	37,176	142,375	37,176
Warrants	457,649	461,649	457,649	461,649

Summary of Finance Lease and Op

Summary of Finance Lease and Operating Lease by Lessee Explanatory (Details) $ in Thousands	Sep. 30, 2022 USD ($)
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	$ 11,640
Less than 1 Year [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	8,876
1 - 3 Years [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	2,718
4 - 5 Years [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	46
More than 5 Years [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net
Services and Manufacturing [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	9,141
Services and Manufacturing [member] | Less than 1 Year [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	7,006
Services and Manufacturing [member] | 1 - 3 Years [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	2,089
Services and Manufacturing [member] | 4 - 5 Years [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	46
Services and Manufacturing [member] | More than 5 Years [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net
R&D contracts [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	2,499
R&D contracts [member] | Less than 1 Year [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	1,870
R&D contracts [member] | 1 - 3 Years [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	629
R&D contracts [member] | 4 - 5 Years [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net
R&D contracts [member] | More than 5 Years [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net

Summary of Research and Develop

Summary of Research and Development and Revenue Related Milestone Payments Explanatory (Details) $ in Thousands	Sep. 30, 2022 USD ($)
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments	$ 45,965
R&D milestone payments [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments	8,527
Revenue Milestone Payments [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments	37,438
Less than 1 Year [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments	24
Less than 1 Year [member] | R&D milestone payments [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments	24
Less than 1 Year [member] | Revenue Milestone Payments [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments
1 - 3 Years [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments	198
1 - 3 Years [member] | R&D milestone payments [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments	198
1 - 3 Years [member] | Revenue Milestone Payments [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments
4 - 5 Years [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments	1,243
4 - 5 Years [member] | R&D milestone payments [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments	1,243
4 - 5 Years [member] | Revenue Milestone Payments [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments
More than 5 Years [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments	44,500
More than 5 Years [member] | R&D milestone payments [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments	7,062
More than 5 Years [member] | Revenue Milestone Payments [member]
IfrsStatementLineItems [Line Items]
R&D and revenue-related milestone payments	$ 37,438

Commitments (Details Narrative)

Commitments (Details Narrative) $ in Thousands, € in Millions, £ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Sep. 30, 2022 GBP (£)
IfrsStatementLineItems [Line Items]
Potential milestone payments description	the Company expects to pay $8,527 including $6,394 (€6.5 million), and $1,283 (£1.2 million) and $850 USD, in R&D milestone payments and up to $37,438, including $27,043 (€27.6 million); $1,395 (£1.3 million) and $9,000 USD, in revenue related milestone payments.	the Company expects to pay $8,527 including $6,394 (€6.5 million), and $1,283 (£1.2 million) and $850 USD, in R&D milestone payments and up to $37,438, including $27,043 (€27.6 million); $1,395 (£1.3 million) and $9,000 USD, in revenue related milestone payments.	the Company expects to pay $8,527 including $6,394 (€6.5 million), and $1,283 (£1.2 million) and $850 USD, in R&D milestone payments and up to $37,438, including $27,043 (€27.6 million); $1,395 (£1.3 million) and $9,000 USD, in revenue related milestone payments.
Research and Development Contracts [member]
IfrsStatementLineItems [Line Items]
Potential milestone payments	$ 8,527	€ 6.5	£ 1.2
R&D milestone payments [member]
IfrsStatementLineItems [Line Items]
Potential milestone payments	37,438	€ 27.6	£ 1.3
Revenue Milestone Payments [member]
IfrsStatementLineItems [Line Items]
Potential milestone payments	$ 9,000